Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 94Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 3Combivir

02 1Delstrigo

03 6Dovato

04 1Epzicom

05 6Epzicom/Kivexa

06 10Triumeq

07 3Trizivir

08 5Zeffix

PharmaCompass

01

Brand Name : Dovato

Dolutegravir, Lamivudine

arrow
iPHEX India
Not Confirmed

02

Brand Name : Triumeq

Dolutegravir, Lamivudine

arrow
iPHEX India
Not Confirmed

03

Brand Name : Epzicom/Kivexa

Dolutegravir, Lamivudine

arrow
iPHEX India
Not Confirmed

Brand Name : Epzicom/Kivexa

arrow
iPHEX India
Not Confirmed

Dolutegravir, Lamivudine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 43

2019 Revenue in Millions : 104

Growth (%) : -59

blank

04

Brand Name : Triumeq

Dolutegravir, Lamivudine

arrow
iPHEX India
Not Confirmed

05

Brand Name : Dovato

Dolutegravir, Lamivudine

arrow
iPHEX India
Not Confirmed

06

Brand Name : Triumeq

Dolutegravir, Lamivudine

arrow
iPHEX India
Not Confirmed

Brand Name : Triumeq

arrow
iPHEX India
Not Confirmed

Dolutegravir, Lamivudine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2022 Revenue in Millions : 2,218

2021 Revenue in Millions : 2,547

Growth (%) : -13

blank

07

Brand Name : Dovato

Dolutegravir, Lamivudine

arrow
iPHEX India
Not Confirmed

Brand Name : Dovato

arrow
iPHEX India
Not Confirmed

Dolutegravir, Lamivudine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2022 Revenue in Millions : 1,695

2021 Revenue in Millions : 1,065

Growth (%) : 59

blank

08

Brand Name : Dovato

Dolutegravir, Lamivudine

arrow
iPHEX India
Not Confirmed

Brand Name : Dovato

arrow
iPHEX India
Not Confirmed

Dolutegravir, Lamivudine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2023 Revenue in Millions : 1,963

2022 Revenue in Millions : 1,695

Growth (%) : 32

blank

09

Brand Name : Triumeq

Dolutegravir, Lamivudine

arrow
iPHEX India
Not Confirmed

Brand Name : Triumeq

arrow
iPHEX India
Not Confirmed

Dolutegravir, Lamivudine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2023 Revenue in Millions : 1,664

2022 Revenue in Millions : 2,218

Growth (%) : -14

blank

10

Brand Name : Dovato

Dolutegravir, Lamivudine

arrow
iPHEX India
Not Confirmed

Brand Name : Dovato

arrow
iPHEX India
Not Confirmed

Dolutegravir, Lamivudine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2024 Revenue in Millions : 2,785

2023 Revenue in Millions : 1,963

Growth (%) : 42

blank